News

ORYZON Raises €30 Million in Capital Increase

Issued 12,765,958 new sharesPriced at €2.35 per share, representing a 15.44% discount on the 5-day VWAPStrong investor demand, with the…

8 months ago

ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status

WESTON, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company…

8 months ago

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from…

8 months ago

Nerve Renew Under Review & Ingredients Guide | Best Nerve Pain Supplement Explained

Nerve Renew is a dietary supplement formulated to support nerve health, particularly for individuals experiencing symptoms of peripheral neuropathy such…

8 months ago

Tonic Greens Review: Will TonicGreens Supplement Work for Immune Support? Read Tonic Greens Official Report!

Tonic Greens is a dietary supplement formulated with a blend of natural superfoods, antioxidants, and immune-supporting ingredients. It's often promoted…

8 months ago

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

(IMAGES BELOW) Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast cancer patientTreatment…

8 months ago

Kura Oncology to Report First Quarter 2025 Financial Results

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed…

8 months ago

Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round

Funding supports the commercial product development of VisioLite® Device and Laser Scleral Microporation Human Clinical Study. Capital raised to date…

8 months ago

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully…

8 months ago

Amwell® to participate in upcoming investor conferences

BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled…

8 months ago